Literature DB >> 2185275

Pathogenesis of an experimental model of Goodpasture's hemorrhagic pneumonitis.

T H Queluz1, I Pawlowski, M J Brunda, J R Brentjens, A O Vladutiu, G Andres.   

Abstract

The mechanisms that allow circulating basement membrane antibodies (Ab) to interact with the alveolar basement membrane (ABM) inducing Goodpasture's hemorrhagic pneumonitis are unknown. In laboratory animals the ABM is inaccessible to phlogogenic amounts of ABM Ab unless the permeability of the unfenestrated alveolar endothelium is increased. This study was designed to test the hypothesis that in the mouse polypeptide mediators, generated by activated lymphoid cells or cells infected by viruses, contribute to the pathogenesis of passive Goodpasture's hemorrhagic pneumonitis. In naive mice that received rabbit ABM Ab, these bound to the glomerular basement membrane but not to the ABM and their lungs were normal. In the lungs of mice injected with human recombinant IL-2 and IFN-alpha specific binding of ABM IgG, C3, and fibrinogen to the ABM, diffuse and severe erythrocyte extravasation, and accumulation of mononuclear and polymorphonuclear leukocytes were constantly observed. ABM Ab and IL-2 or ABM Ab and IFN-alpha did not produce comparable effects. Mice injected only with IL-2 and IFN-alpha had enlarged, edematous lungs without pulmonary hemorrhages. The results show that the synergism of IL-2 and IFN-alpha convert the lung into a preferential target for AMB Ab, suggesting that cytokines may have a role in the pathogenesis of human Goodpasture's pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2185275      PMCID: PMC296598          DOI: 10.1172/JCI114597

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

1.  Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.

Authors:  M J Brunda; D Tarnowski; V Davatelis
Journal:  Int J Cancer       Date:  1986-05-15       Impact factor: 7.396

Review 2.  Human natural killer cells: biologic and pathologic aspects.

Authors:  G Trinchieri; B Perussia
Journal:  Lab Invest       Date:  1984-05       Impact factor: 5.662

3.  Specific molecular activities of recombinant and hybrid leukocyte interferons.

Authors:  E Rehberg; B Kelder; E G Hoal; S Pestka
Journal:  J Biol Chem       Date:  1982-10-10       Impact factor: 5.157

4.  Experimental anti-alveolar basement membrane antibody-mediated pneumonitis. II. Role of endothelial damage and repair, induction of autologous phase, and kinetics of antibody deposition in Lewis rats.

Authors:  G H Downie; O A Roholt; L Jennings; M Blau; J R Brentjens; G A Andres
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

5.  Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.

Authors:  M J Brunda; D Rosenbaum
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

6.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

Review 7.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

8.  Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells.

Authors:  J S Pober; M P Bevilacqua; D L Mendrick; L A Lapierre; W Fiers; M A Gimbrone
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

9.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  3 in total

1.  Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth.

Authors:  F Cozzolino; M Torcia; M Lucibello; L Morbidelli; M Ziche; J Platt; S Fabiani; J Brett; D Stern
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

2.  Pulmonary expression of ICAM-1 and LFA-1 in experimental Goodpasture's syndrome.

Authors:  P A Hill; H Y Lan; D J Nikolic-Paterson; R C Atkins
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

3.  Suppression of pulmonary injury in experimental 'Goodpasture's syndrome' by deoxyspergualin (DSP).

Authors:  H Y Lan; D J Nikolic-Paterson; M Zarama; P G Kerr; R C Atkins
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.